Lou Gehrig’s disease, also called amyotrophic lateral sclerosis (ALS), is a serious nerve disease that slowly damages the motor neurons—the special nerve cells in the brain and spinal cord that tell your muscles to move. “Amyotrophic” means “no muscle nourishment,” “lateral” refers to the side parts of the spinal cord where many motor pathways run, and “sclerosis” means “hardening” or scarring of tissue. In ALS, these motor neurons gradually stop working and die. As this happens, the muscles they control become weak, shrink, and stiff. People may notice trouble with hand strength, walking, speaking, swallowing, or breathing. Thinking and personality are often normal at first, but some people also develop changes in behavior or thinking linked to frontotemporal dementia. ALS does not usually affect senses like sight, hearing, smell, or touch, and it does not usually affect bowel or bladder control early on. The condition progresses over time at different speeds for different people.
ALS is a progressive disease that damages the nerve cells (motor neurons) that control muscles. Over time, muscles become weak and shrink, making it harder to move, speak, swallow, and breathe. Thinking and personality are usually normal, but some people develop changes in behavior or memory. ALS can be sporadic (most cases) or familial (inherited, fewer cases). There is no cure yet, but specific medicines, breathing support, nutrition support, and team-based care can slow the disease and improve quality of life. NINDS+1
Why ALS happens
In ALS, motor neurons in the brain and spinal cord gradually die. Many processes likely contribute: glutamate excitotoxicity, oxidative stress, abnormal protein handling/aggregation, mitochondrial problems, inflammation, and RNA processing errors. Some genes (for example C9orf72, SOD1, TARDBP, FUS) can cause or raise the risk of ALS, especially in familial cases. About 90–95% of cases are sporadic and 5–10% are familial. PMC+2PMC+2
Other names
Lou Gehrig’s disease – common U.S. name, after the famous baseball player who had ALS.
Amyotrophic lateral sclerosis (ALS) – the medical name.
Motor neuron disease (MND) – umbrella term used in many countries; ALS is the most common type of MND.
Charcot disease – historical name in Europe, after the neurologist Jean-Martin Charcot who described it.
ALS–FTD – ALS with frontotemporal dementia features (an overlap syndrome in some people).
Types and clinical patterns
ALS is one disease, but it can start and look different from person to person. Doctors often describe patterns rather than strict subtypes:
Limb-onset ALS (arm or leg first)
Weakness starts in a hand, arm, foot, or leg. People may notice dropping objects, poor grip, foot drop, tripping, or trouble with buttons. This is the most common starting pattern.Bulbar-onset ALS (speech or swallow first)
The first problems are slurred or nasal speech, a soft or strained voice, choking on water or food, drooling, or a fast gag reflex. This is more common in older adults and in women.Respiratory-onset ALS (breathing first)
Early shortness of breath, especially when lying flat, weak cough, morning headaches, or poor sleep due to shallow breathing. This form is less common but important to recognize.Upper-motor-neuron–predominant pattern (PLS-like)
Stiffness, slowed movement, and very brisk reflexes are the main signs at first. Over time, classic ALS features can appear. Primary lateral sclerosis (PLS) is related but usually slower.Lower-motor-neuron–predominant pattern (PMA-like)
Wasting and twitching of muscles with weakness from the start, fewer signs of stiffness or brisk reflexes early on. Progressive muscular atrophy (PMA) is related and may evolve to ALS.Regional variants
Flail-arm (brachial diplegia): shoulder and arm weakness on both sides, with wasting and drooping of the arms.
Flail-leg (peroneal diplegia): both legs become weak and wasted first, leading to foot drop and tripping.
ALS with cognitive/behavioral change (ALS–FTD)
In some people, changes in judgment, planning, empathy, eating habits, or language appear along with movement problems, due to frontotemporal lobar degeneration.
Causes and contributors
Important note: For most people with ALS, a single clear cause is not known. Scientists believe ALS often results from a mix of genetic susceptibility and environmental or biological stressors accumulated over time. Below are known causes (especially in familial ALS) and risk/contributing factors that research has linked to ALS. Where a factor is strongly proven, it is labeled clearly; where evidence is mixed or suggestive, that is noted.
Genetic mutations with strong evidence (familial ALS ~5–10%)
Changes in genes such as C9orf72, SOD1, TARDBP (TDP-43), and FUS can cause inherited ALS. These mutations damage nerve cells through toxic proteins, RNA problems, or stress responses.C9orf72 hexanucleotide repeat expansion
The most common genetic cause in many countries. Abnormal repeated DNA segments lead to toxic RNA and harmful dipeptide proteins that injure motor neurons.SOD1 mutations
Faulty SOD1 proteins misfold and form clumps, disrupt cell clean-up systems, and create oxidative stress, which harms motor neurons.TDP-43 proteinopathy (linked to TARDBP and beyond)
Misplaced or clumped TDP-43 protein is found in most ALS cases (even without a TARDBP mutation). It interferes with RNA handling and normal cell function.FUS mutations
Abnormal FUS protein disrupts RNA processing and forms aggregates that are toxic to neurons.Age (strong, non-modifiable risk)
Risk rises with age, most often starting between 55 and 75. Aging cells are less resilient to stress and repair.Male sex (modest risk difference)
Men are affected slightly more often than women, especially in earlier age groups, although this gap narrows with age.Family history without known gene
Some families show clustering of ALS or frontotemporal dementia even when a clear gene abnormality has not been identified yet.Glutamate excitotoxicity (biological mechanism)
Excess glutamate—the main excitatory brain chemical—can overstimulate neurons, allowing too much calcium into cells and triggering cell death pathways.Oxidative stress and mitochondrial dysfunction
Reactive oxygen species and unhealthy mitochondria (the cell’s power plants) can damage DNA, proteins, and membranes in motor neurons.Protein misfolding and impaired autophagy
Neurons need to fold proteins correctly and recycle damaged ones. When these systems fail, toxic protein clumps accumulate and injure cells.Neuroinflammation and microglial activation
Immune cells in the brain and spinal cord (microglia and astrocytes) can switch into a harmful state and release substances that damage neurons.Axonal transport failure
Motor neurons are long cells that rely on “rails” to move nutrients and signals. When transport breaks down, the far ends of the neurons starve.Environmental exposures (mixed evidence)
Studies suggest possible links with certain pesticides, solvents, heavy metals, or cyanobacterial toxins (e.g., BMAA). Not all studies agree, but reducing exposure is reasonable.Smoking (modifiable risk)
Smoking has been associated with a higher risk of ALS in several studies, possibly due to oxidative stress or toxins.Intense physical exertion over decades (debated)
Some research suggests higher ALS rates in people with long careers of intense physical activity (e.g., certain athletes), but findings are not consistent across studies.Head trauma history (debated)
Repeated head injuries may raise risk in some studies, but evidence is mixed.Military service (association)
A higher rate of ALS has been observed in some groups of military veterans. Reasons are unclear and may include multiple exposures.Metabolic and gut factors (emerging)
Abnormal energy use, weight loss before diagnosis, and gut microbiome differences are being studied as contributors to disease stress.Viral or immune triggers (theories under study)
Prior viral infections or autoimmune reactions may act as triggers in vulnerable people, but firm proof is limited.
Common symptoms
Muscle weakness
You may notice weaker hands, arms, legs, or feet. Tasks like turning keys, lifting, climbing stairs, or getting up from a chair become harder.Muscle wasting (atrophy)
Muscles shrink because the nerve supply is failing. You might see hollows around the hands, shoulders, thighs, or calves.Muscle twitching (fasciculations)
Small, rippling twitches under the skin, often in the arms, shoulders, tongue, or legs. They can be annoying but are not painful by themselves.Muscle cramps and stiffness (spasticity)
Tight or rigid muscles, spasms, or painful cramps—especially in the calves and hands—due to loss of normal nerve control.Clumsy hands and poor fine motor control
Buttons, zippers, typing, or writing get slow and sloppy. Grip strength can fade, and objects are dropped more often.Walking problems and foot drop
The front of the foot may drag (foot drop), causing tripping. Steps look short and unsteady, and the person may need an ankle brace or cane.Speech changes (dysarthria)
Speech can sound slurred, soft, nasal, or strained. People may be hard to understand on the phone or when they are tired.Swallowing trouble (dysphagia) and drooling
Thin liquids choke, pills stick, or chewing is slow. Saliva may pool because swallowing is weak, leading to drooling.Breathing trouble
Shortness of breath, especially when lying flat; poor sleep; morning headaches; or daytime sleepiness—signs of weak breathing muscles.Weak cough and frequent chest infections
Clearing mucus is hard. Colds can turn into chest infections more easily.Emotional lability (pseudobulbar affect)
Sudden laughing or crying that is hard to control, even when the feelings are not that strong.Fatigue and low energy
Daily tasks feel exhausting. Rest breaks become necessary.Weight loss
Muscles burn extra energy because they work inefficiently, and eating may be slow. This leads to unwanted weight loss.Pain and discomfort
Pain is not from the nerves themselves but from cramps, stiff muscles, poor posture, and pressure on joints or skin.Thinking or behavior changes (in some people)
Problems with planning, judgment, word finding, or social behavior can appear, especially in ALS–FTD.
Diagnostic tests
A) Physical exam–based evaluations
Full neurological exam
The doctor checks strength, muscle size, tone, reflexes, coordination, and sensation. In ALS, there is a characteristic mix of upper motor neuron signs (stiffness, brisk reflexes, Babinski sign) and lower motor neuron signs (wasting, twitching, weak reflexes).Manual muscle strength grading (MRC scale)
Strength of each major muscle group is compared side-to-side and scored from 0 (no movement) to 5 (normal). This creates a baseline to track change.Reflex and plantar response testing
Brisk reflexes, clonus (repeated beats), and an up-going big toe (Babinski) point to upper motor neuron involvement, which supports ALS when combined with weakness and wasting.Bulbar function exam (speech and swallow)
The clinician listens for slurred, nasal, or strained speech; examines the tongue for wasting and fasciculations; and checks gag and jaw-jerk reflexes. These findings help confirm bulbar involvement.Respiratory muscle assessment at bedside
Observing chest movement, checking for use of neck muscles to breathe, and listening for weak cough can suggest early breathing weakness.
B) Manual/bedside functional tests
Manual Muscle Testing (MMT) by joint action
The examiner resists specific movements (like wrist extension or ankle dorsiflexion) to grade real-world power and identify patterns such as foot drop.Single-breath count
The person counts out loud after a deep breath. A lower count for age/size can hint at reduced vital capacity and early breathing involvement.Simple bedside swallow test (e.g., small-volume water test)
A measured sip of water or semi-solid is given while watching for coughing, throat clearing, or voice change. This screens for aspiration risk and guides safer textures.Gait assessment (heel, toe, and tandem walking)
Trouble walking on heels suggests foot drop; inability to tandem walk shows balance issues; careful observation exposes compensations and fall risk.
C) Laboratory and pathological tests (mainly to exclude mimics and to document genetics)
Serum creatine kinase (CK)
CK can be mildly elevated due to muscle breakdown but is usually not very high. A very high CK would push doctors to consider a primary muscle disease instead.Thyroid function and vitamin B12 (± methylmalonic acid)
Low thyroid or low B12 can cause weakness or neuropathy that look similar to ALS. Correcting these treats the problem if they are the real cause.Autoimmune and paraneoplastic panels (e.g., anti-GM1)
Certain immune-mediated nerve diseases, such as multifocal motor neuropathy (often anti-GM1 positive), can mimic ALS but do respond to treatment like IVIG—so testing matters.Infection screens (HIV, HTLV-1, Lyme where relevant)
Infections can sometimes cause motor neuropathies or myelopathies. Positive results shift care toward targeted treatment.Cerebrospinal fluid (CSF) analysis
A lumbar puncture can show inflammation, infection, or other clues to alternative diagnoses. In classic ALS, CSF is often normal or nonspecific.Genetic testing for ALS genes
Testing for C9orf72, SOD1, TARDBP, FUS, and others is recommended when there is a family history, early onset, or certain patterns. Genetic counseling is important before and after testing.Muscle biopsy (select cases)
Rarely used for classic ALS, but it helps when a primary muscle disorder is suspected. It can show patterns of denervation or a different disease altogether.
D) Electrodiagnostic tests (core to ALS diagnosis)
Electromyography (EMG)
EMG looks at the electrical activity of muscles. In ALS it shows active denervation (fibrillations, positive sharp waves) and chronic reinnervation (large motor units), in several body regions. It is a key test that supports the diagnosis.Nerve conduction studies (NCS)
NCS help rule out demyelinating neuropathies and motor neuron mimics. In ALS, motor responses may be reduced, while sensory studies are usually normal.Transcranial magnetic stimulation (TMS) / Motor evoked potentials
These can detect upper motor neuron pathway dysfunction by measuring how signals travel from the brain to muscles. They complement EMG/NCS in difficult cases.
E) Imaging tests
MRI of brain and spinal cord (± diaphragm ultrasound)
MRI helps exclude structural problems like cervical spondylotic myelopathy, tumors, or multiple sclerosis lesions. Diaphragm ultrasound, when used, can show reduced movement of the main breathing muscle.
Non-pharmacological treatments (therapies & others)
(Each item includes purpose & mechanism in simple terms. Evidence highlights focus on survival/quality-of-life-improving strategies.)
Multidisciplinary ALS clinic care
Purpose: Coordinate care in one place (neurologist, respiratory therapist, dietitian, PT/OT, speech therapist, social worker).
Mechanism: Regular team reviews anticipate problems and start help earlier (for example, breathing support, nutrition, equipment). This approach improves survival and life quality. PubMed+2PMC+2Non-invasive ventilation (NIV/BiPAP)
Purpose: Support breathing during sleep and later during the day to reduce breathlessness and fatigue.
Mechanism: A face or nasal mask assists weak breathing muscles, improving oxygen–carbon dioxide balance and sleep. NIV extends life and improves symptoms. PMC+1Breathing muscle monitoring & cough assistance
Purpose: Check lung function regularly; help clear mucus.
Mechanism: Periodic spirometry/FVC identifies decline early; cough-assist devices and suction remove secretions to prevent infection and distress. Guidelines endorse structured respiratory care. American Academy of NeurologyNutrition optimization & texture-modified diet
Purpose: Prevent weight loss, dehydration, and aspiration.
Mechanism: High-calorie, high-protein meals and thickened liquids reduce choking risk and help maintain strength. Early dietitian input matters. American Academy of NeurologyTimely feeding-tube support (PEG or RIG)
Purpose: Maintain safe, adequate nutrition/hydration when swallowing is unsafe.
Mechanism: A tube into the stomach bypasses weak swallowing muscles. Best considered before lung function falls too low (often discussed before FVC <50%). PMC+2UVA School of Medicine+2Speech & swallowing therapy
Purpose: Keep communication clear and swallowing safer for longer.
Mechanism: Strategies for pacing speech, posture, head positioning, and swallow techniques; early training in communication tools if speech declines. Mayo ClinicAugmentative & alternative communication (AAC)
Purpose: Maintain communication when speech weakens.
Mechanism: From low-tech (letter boards) to high-tech (text-to-speech, eye-gaze). “Voice banking” preserves one’s own voice for later. Multidisciplinary programs integrate AAC early. The ALS AssociationPhysical therapy (PT) & gentle exercise
Purpose: Preserve flexibility, reduce stiffness and cramps, maintain safe mobility.
Mechanism: Range-of-motion, stretching, low-to-moderate aerobic work as tolerated; balance and transfer training; bracing to support weak joints. American Academy of NeurologyOccupational therapy (OT) & home modifications
Purpose: Keep daily activities safe and efficient.
Mechanism: Energy-saving techniques; adaptive equipment (grab bars, raised seats, utensils); wheelchair/mobility assessments to reduce falls and overexertion. Archives PMRPalliative care (from early on)
Purpose: Treat symptoms thoroughly, plan ahead, support emotional well-being for patient and family.
Mechanism: Expert symptom control (breathlessness, anxiety, sleep, pain), advance-care planning, and caregiver support alongside usual care. Multidisciplinary models embed this approach. Quest | Muscular Dystrophy AssociationSleep optimization
Purpose: Reduce morning headaches, fatigue, and poor concentration linked to nighttime hypoventilation.
Mechanism: Sleep studies, NIV, and sleep-hygiene support improve restorative rest. PMCAirway secretion management (non-drug tools)
Purpose: Reduce drooling and choking.
Mechanism: Portable suction, mechanical insufflation–exsufflation (cough-assist), and positioning techniques complement medications if needed. American Academy of NeurologyPsychological support & peer groups
Purpose: Protect mental health; reduce isolation.
Mechanism: Counseling, peer groups, and caregiver support improve coping and quality of life. The ALS AssociationSafety & fall-prevention program
Purpose: Avoid injuries and hospitalizations.
Mechanism: Home hazard review, gait aids, caregiver training for transfers, and fatigue management. Archives PMRAdvance care planning
Purpose: Make sure care reflects your priorities as disease progresses.
Mechanism: Discuss preferences on feeding tubes, NIV, tracheostomy, and hospice early with the care team. American Academy of NeurologyCaregiver training
Purpose: Improve safety and reduce caregiver strain.
Mechanism: Instruction on lifts, skin care, nutrition, and equipment use; linking to respite resources. Archives PMRWork/finance/social services navigation
Purpose: Maintain dignity and reduce stress.
Mechanism: Social workers help with disability benefits, equipment funding, and community resources. The ALS AssociationRegular reassessment schedule
Purpose: Start supports (NIV, PEG, AAC) at the right time.
Mechanism: Tracking ALSFRS-R, weight, FVC, swallowing status at each visit. American Academy of NeurologyVaccinations & infection prevention
Purpose: Avoid setbacks from flu, pneumonia, and COVID-19.
Mechanism: Staying current on vaccines and hand/respiratory hygiene lowers complications. (General best practice across neuromuscular disorders.) MedlinePlusClinical trial participation (when interested/eligible)
Purpose: Access investigational therapies; contribute to progress.
Mechanism: Genetic testing may guide eligibility (e.g., SOD1). The care team can refer to reputable trial registries. PMC
Drug treatments
⚠️ Important: The following are general information points. Dosing and timing must be individualized by your clinician (liver/kidney function, drug interactions, pregnancy status, symptom pattern, goals of care). Do not start/stop/change any medicine without your doctor.
Riluzole
Class: Glutamate-release modulator.
Typical dose: 50 mg by mouth every 12 hours (take on an empty stomach). Start soon after diagnosis unless contraindicated.
Purpose: Modestly prolongs survival/slow progression.
Mechanism: Reduces glutamate-mediated excitotoxicity in motor neurons.
Common side effects: Nausea, fatigue; liver enzyme elevations—monitor labs regularly. Drugs.com+1Edaravone (RADICAVA / RADICAVA ORS)
Class: Free-radical scavenger (antioxidant).
Typical dosing (IV): 60 mg infusions in cycles; oral suspension also available with cycle-based dosing per label.
Purpose: Slows functional decline in selected patients.
Mechanism: Limits oxidative stress injury in motor neurons.
Side effects: Bruising, gait issues, headache; rare hypersensitivity/anaphylaxis (sulfite allergy caution). FDA Accessibility Data+1Tofersen (Qalsody) — for confirmed SOD1-ALS
Class: Antisense oligonucleotide (gene-directed therapy).
Typical dosing: Intrathecal loading then maintenance per label in specialist centers.
Purpose: Targets the mutant SOD1 transcript to reduce toxic protein; approved on accelerated basis using neurofilament reduction as a surrogate.
Side effects: Headache, procedural back pain, CSF pleocytosis; requires specialist monitoring. Biogen Investors+1Dextromethorphan/Quinidine (Nuedexta)
Class: NMDA modulation + CYP2D6 inhibitor combo.
Dose: Per label; often 20/10 mg once daily for 7 days, then 20/10 mg twice daily (clinician-directed).
Purpose: Treats pseudobulbar affect (sudden laughing/crying).
Mechanism: Modulates brain circuits that control emotional expression.
Side effects: Dizziness, diarrhea; QT prolongation and drug interactions—cardiac review needed. PMC+1Baclofen (oral)
Class: Antispasticity (GABA-B agonist).
Typical dose: Start low (e.g., 5 mg 2–3×/day) and titrate; maximum varies.
Purpose: Reduces stiffness and spasms.
Mechanism: Lowers spinal reflex activity.
Side effects: Sleepiness, weakness, dizziness; taper slowly to avoid withdrawal. MedscapeTizanidine
Class: Alpha-2 adrenergic agonist antispastic.
Dose: Titrated low-and-slow; liver function monitoring.
Purpose/Mechanism: Reduces spasticity by decreasing excitatory signals in spinal cord.
Side effects: Sedation, dry mouth, hypotension, liver enzyme rise. American Academy of NeurologyIntrathecal baclofen (ITB) pump
Class: Antispasticity via spinal delivery.
Dose: Continuous programmable infusion after test dose.
Purpose: For severe spasticity not helped by pills.
Mechanism: Direct spinal action with lower systemic exposure.
Risks: Pump/catheter issues, infection, overdose/withdrawal risks—requires specialized team. American Academy of NeurologyMexiletine
Class: Sodium-channel blocker (antiarrhythmic) used off-label.
Typical dose: Often 150 mg twice daily, adjusted by clinician.
Purpose: Reduces painful muscle cramps in ALS.
Mechanism: Stabilizes over-excitable nerve/muscle membranes.
Side effects: Heartburn, dizziness; rare arrhythmia—cardiac history review needed. PMCGlycopyrrolate / Atropine drops / Scopolamine patch
Class: Anticholinergics.
Purpose: Treat troublesome drooling (sialorrhea).
Mechanism: Reduce saliva production.
Side effects: Dry mouth, constipation, blurred vision, confusion (elderly sensitive)—use carefully. If meds fail, botulinum toxin or low-dose salivary gland radiation can help. Medscape+1Botulinum toxin injections (salivary glands)
Class: Neurotoxin injected into parotid/submandibular glands.
Dose: Specialist-determined units per gland.
Purpose: Longer-lasting drooling control.
Mechanism: Temporarily blocks acetylcholine release, reducing saliva.
Side effects: Thickened saliva, swallowing discomfort; benefit usually months. American Academy of NeurologyAmitriptyline (low dose at night)
Class: Tricyclic antidepressant.
Purpose: Helps drooling (dries secretions), mood, and sleep.
Mechanism: Anticholinergic and serotonergic effects.
Side effects: Dry mouth, constipation, sedation, QT prolongation—clinician monitoring needed. MedscapeSSRIs/SNRIs (e.g., sertraline, venlafaxine)
Class: Antidepressants/anxiolytics.
Purpose: Treat depression/anxiety; sometimes help pseudobulbar lability.
Mechanism: Boost serotonin/norepinephrine signaling.
Side effects: Nausea, sleep change, sexual dysfunction; watch for interactions. Mayo ClinicShort-acting anxiolytics for procedures or NIV acclimation
Class: Benzodiazepines (cautious, low dose).
Purpose: Ease NIV adaptation or procedure anxiety.
Mechanism: GABA-A modulation reduces anxiety.
Side effects: Sedation and respiratory depression—use sparingly and only with clinician oversight. American Academy of NeurologySecretolytics/antisecretory adjuvants
Class: E.g., atropine sublingual drops before meals.
Purpose/Mechanism: Short-term drooling control during meals.
Side effects: As above for anticholinergics. MedscapeConstipation regimen
Class: Osmotic/stimulant laxatives as needed.
Purpose: Comfort and medication tolerance.
Mechanism: Soften stools and promote bowel movement.
Side effects: Bloating, cramping—titrate. American Academy of NeurologyPain control (acetaminophen/NSAIDs; neuropathic agents as needed)
Purpose: Treat musculoskeletal pain or neuropathic patterns.
Mechanism: Anti-inflammatory/central modulation.
Risks: GI, kidney, bleeding (NSAIDs); dosing individualized. American Academy of NeurologyAntireflux therapy if reflux worsens cough/aspiration risk
Class: PPIs/H2 blockers when indicated.
Purpose: Reduce reflux that can worsen breathing at night.
Mechanism: Lowers stomach acid.
Risks: Long-term PPI cautions; clinician guides use. American Academy of NeurologySialorrhea radiation (if meds/botox fail)
Class: Low-dose salivary gland radiotherapy.
Purpose: Longer-term drooling control.
Mechanism: Reduces gland secretion.
Risks: Dry mouth, taste change; planned by radiation oncologist. PubMedSleep/insomnia aids (cautious)
Class: Melatonin or clinician-selected agents.
Purpose: Improve restorative sleep while prioritizing breathing support.
Mechanism: Circadian support; avoid respiratory suppression. American Academy of Neurology(Withdrawn) Sodium phenylbutyrate/taurursodiol (AMX0035; Relyvrio)
Status: Voluntarily withdrawn in 2024 after a negative Phase 3 trial; not available for new patients in the U.S./Canada. Existing users were transitioned via a limited program. This entry is here purely to clarify status. amylyx.com+2neurologylive.com+2
Dietary molecular supplements
⚠️ No supplement has proven to cure or clearly slow ALS. Discuss any supplement with your clinician to avoid interactions and cost without benefit.
Vitamin D: Important for bone and muscle health; deficiency is treated per guidelines, but no proof of disease-modifying effect in ALS. Mayo Clinic
Omega-3 fatty acids: Anti-inflammatory properties; overall health benefits; ALS-specific benefit unproven. Mayo Clinic
Creatine: Supports muscle energy buffering; ALS trials have not shown clear clinical benefit. Mayo Clinic
Coenzyme Q10: Antioxidant; ALS trials negative for slowing progression. Mayo Clinic
Vitamin B12 (methylcobalamin, high-dose): Investigational signals in some studies, but routine use for ALS modification is unproven; treat deficiency if present. CDC Stacks
Alpha-lipoic acid: Antioxidant; ALS-specific benefit unproven. Mayo Clinic
Acetyl-L-carnitine: Mitochondrial cofactor; data in ALS are inconclusive. Mayo Clinic
Curcumin / resveratrol: Anti-inflammatory/antioxidant; human ALS benefit not proven. Mayo Clinic
Magnesium: For cramps, evidence in ALS is weak; mexiletine has better support for cramps. PMC
Zinc or selenium: Do not use high doses; no ALS benefit and excess may be harmful. Always review with clinician. Mayo Clinic
Immunity-booster / regenerative / stem-cell drugs
⚠️ No stem-cell product or “immune booster” is FDA-approved for ALS. These approaches are investigational and should only be accessed in regulated clinical trials, not in commercial clinics.
Antisense oligonucleotides (ASOs) beyond SOD1 (e.g., targeting C9orf72): Gene-directed therapies are in trials; mechanism is lowering toxic transcripts. Status: investigational. PMC
Cell-based therapies (e.g., mesenchymal stem cells): Aim to release growth factors/anti-inflammatory signals; not approved; mixed trial results. Use only in trials. PMC
Neuroinflammation modulators (e.g., masitinib): Tyrosine kinase inhibitor studied with mixed outcomes; not approved. Medscape
Mitochondrial/oxidative agents “next-gen”: Various compounds under study; none approved for disease modification as of now. Mayo Clinic
Gene-editing concepts (CRISPR, base editors): Theoretical/early preclinical for ALS; not available clinically. PMC
Immune modulators (low-dose IL-2, others): Explored to shift neuroinflammation; results insufficient for approval. Trial-only. PMC
Procedures / surgeries
Percutaneous Endoscopic Gastrostomy (PEG)
What it is: A camera-guided tube placed through the belly into the stomach.
Why done: To maintain safe nutrition/hydration when swallowing is unsafe. Often discussed before FVC <50% to reduce risks. PMC+1Radiologically Inserted Gastrostomy (RIG/PRG)
What it is: Feeding tube placed under X-ray guidance.
Why done: Alternative when endoscopy is difficult or respiratory reserve is low; chosen by the team based on risk. PMCTracheostomy with invasive ventilation
What it is: A surgical airway with a ventilator.
Why done: For long-term breathing support when NIV is no longer enough, chosen by patient preference and goals of care. American Academy of NeurologyIntrathecal baclofen pump implantation
What it is: A pump placed under the skin delivers baclofen to the spinal fluid.
Why done: Treat severe spasticity not controlled by tablets and rehab measures. American Academy of Neurology**Salivary gland procedures (duct ligation) or low-dose radiation
What it is: Target the glands to decrease saliva when meds/botox fail.
Why done: Control severe drooling to reduce choking and improve comfort. (Radiation is not surgery, but it’s a procedural option.) PubMed
Prevention tips (what we can say)
There is no proven way to prevent ALS, because causes are not fully known. Still, general health steps can reduce complications and support well-being if you’re at risk or living with ALS:
Don’t smoke; avoid second-hand smoke.
Use protective equipment to limit toxin/pesticide exposure.
Practice head/neck injury prevention (helmets, fall prevention).
Keep vaccinations current to prevent infections.
Maintain a healthy weight; unintentional weight loss worsens outcomes.
Stay physically active within safe limits; avoid overexertion.
Manage sleep and treat sleep-disordered breathing promptly.
Treat vitamin deficiencies (especially vitamin D) if present.
Seek early specialist evaluation for progressive weakness—earlier care helps.
Consider genetic counseling/testing if there’s a strong family history. MedlinePlus+1
When to see a doctor—right away
New or progressive weakness in the hands, arms, legs, or speech/swallowing.
Frequent choking, coughing when eating/drinking, or drooling that is hard to control.
Breathlessness, morning headaches, poor sleep, or daytime sleepiness (possible nocturnal hypoventilation).
Sudden emotional outbursts (laughing/crying) that feel out of control.
Unexplained weight loss or dehydration.
Early referral to a neurologist with ALS expertise and an ALS clinic leads to better, faster support. PubMed
What to eat and what to avoid
Eat more of:
High-calorie, high-protein soft meals (eggs, yogurt, smoothies, nut butters).
Moist, soft textures (stews, mashed foods) to reduce effort and choking risk.
Healthy fats (olive oil, avocado) to raise calories easily.
Thickened liquids if your speech/swallow therapist recommends them. American Academy of Neurology
Limit/avoid:
Thin liquids (water, juice) if you aspirate—use thickeners as instructed.
Hard, dry, crumbly foods (nuts, dry crackers) that are easy to choke on.
Alcohol close to bedtime (can worsen sleep and airway protection).
Very spicy/acidic foods if they increase drooling or reflux. American Academy of Neurology
Frequently asked questions (FAQ)
1) Is ALS contagious?
No. ALS does not spread between people. NINDS
2) How is ALS diagnosed?
Doctors use history, neurological exam, EMG/NCS, and tests to rule out mimics. Many centers use the Gold Coast criteria to make diagnosis earlier and more simply. PMC+1
3) What lab or imaging tests might be done?
Blood tests (thyroid, B12, copper), MRI to exclude other problems, and sometimes genetic testing when family history suggests it. EMG shows lower motor neuron involvement. CDC Stacks
4) How long do people live with ALS?
It varies. Average is about 3–5 years after symptom start, but some live 10+ years, especially with strong supportive care and NIV. MedlinePlus
5) What treatments can extend life?
Riluzole, non-invasive ventilation, and timely nutrition support (PEG) have the best evidence for survival benefit; multidisciplinary care improves outcomes. Medscape
6) Are there gene-targeted therapies?
Yes—for SOD1-ALS, tofersen is FDA-approved under the accelerated pathway. Other gene therapies are in trials. The ALS Association
7) What happened to Relyvrio (AMX0035)?
The manufacturer withdrew it in 2024 after a Phase 3 trial failed; it’s no longer available to new patients. amylyx.com+1
8) Can exercise help?
Gentle, supervised activity can aid flexibility and mood; avoid overexertion. PT tailors a safe plan. American Academy of Neurology
9) What about stem cells?
Not FDA-approved for ALS; consider only within regulated clinical trials. PMC
10) How can we control drooling?
Start with positioning and suction. If needed, try anticholinergic medicines; botulinum toxin or low-dose radiation are options if meds fail. Medscape+1
11) Is there help for sudden laughing/crying (pseudobulbar affect)?
Yes: dextromethorphan/quinidine is approved and effective for many. PMC
12) Are muscle cramps treatable?
Yes: mexiletine has randomized-trial evidence to reduce cramps; dosing and cardiac safety must be reviewed by your doctor. PMC
13) Should I bank my voice?
It’s a good idea early; AAC tools can keep you communicating if speech declines. The ALS Association
14) When should we talk about feeding tubes or tracheostomy?
Discuss early with your team so the choice matches your values and timing is safer (PEG often before FVC <50%). PMC+1
15) Where can I find trustworthy information and clinics?
National resources include NINDS/NIH, MedlinePlus, and ALS specialty centers. NINDS+1
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 15, 2025.
